Highlight
This article reviews the importance of early disease clearance in ulcerative colitis (UC), as evidenced by the phase 3 UNIFI program assessing ustekinumab therapy. Key findings include: (1) Disease clearance at 8 weeks post-induction therapy correlates strongly with superior long-term clinical remission and quality of life. (2) Patients achieving simultaneous symptomatic remission and histo-endoscopic mucosal improvement (HEMI) early demonstrate more than double the likelihood of sustained remission at 44 weeks compared to those who do not. (3) Four-year follow-up highlights the potential of ustekinumab as a maintenance therapy to secure durable responses in UC. This underscores the clinical imperative to achieve rapid and complete control of inflammation in UC management.
Study Background and Disease Burden
Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by persistent inflammation of the colonic mucosa, leading to debilitating symptoms including diarrhea, rectal bleeding, and abdominal pain. The disease imposes substantial morbidity and impairs quality of life. Despite advances in therapy, many patients experience relapses and progressive disease, emphasizing the need for strategies that induce durable remission. Emerging evidence supports the concept of disease clearance—defined as simultaneous symptomatic remission and histo-endoscopic mucosal improvement (HEMI)—as a therapeutic target that may prevent long-term complications and reduce healthcare burden. However, prospective data linking early disease clearance with long-term outcomes remain limited.
Study Design
The UNIFI program comprised rigorously designed randomized, placebo-controlled phase 3 induction and maintenance clinical trials of ustekinumab, alongside a long-term extension study. Patients with moderate to severe UC received intravenous ustekinumab induction at doses of 130 mg or approximately 6 mg/kg body weight, followed by subcutaneous maintenance dosing every 8 or 12 weeks (90 mg). The duration extended up to 4 years, evaluating both clinical endpoints and patient-reported outcomes. Disease clearance was assessed at 8 weeks post-induction, encompassing symptomatic remission (Mayo stool frequency subscore 0/1, rectal bleeding subscore 0) and histo-endoscopic mucosal improvement (including endoscopic and histological criteria). Key efficacy assessments included clinical remission using the Mayo Clinic score (≤2 with no subscore >1), symptomatic remission, and quality of life measured by the Inflammatory Bowel Disease Questionnaire (score ≥170).
Key Findings
Disease clearance at 8 weeks was achieved significantly more often in ustekinumab treated groups (15.2% for 130 mg and 15.1% for ~6 mg/kg) versus placebo (5.9%). Among patients who responded to ustekinumab induction and entered maintenance therapy, those attaining disease clearance had a markedly higher clinical remission rate at Week 44 compared to those without clearance (63.6% vs 35.2%, p < 0.001). Further subanalysis showed that patients with disease clearance were more likely to maintain symptomatic remission (73.4%) compared to those with symptomatic remission alone (53.5%) or neither remission (45.1%), with statistically significant differences (p = 0.002 and p < 0.001, respectively). Long-term data at Week 200 reinforced these trends; 58.2% of patients who achieved disease clearance maintained remission reflected in patient-reported outcomes, compared to 46.5% and 42.7% in the other groups, approaching or reaching nominal significance.
These data indicate that achieving comprehensive early disease control through ustekinumab induction translates into better clinical outcomes, symptomatic relief, and quality of life over years. The study also corroborates the critical role of mucosal healing as a biomarker and treatment goal alongside symptom management.
Expert Commentary
These findings align with evolving expert consensus endorsing treat-to-target strategies in UC, where combined endpoints including endoscopic healing guide therapy optimization. Dr. Stefano Danese and colleagues highlight in their publication that early, stringent targets like disease clearance could refine clinical decision-making and prognostication. However, achieving this goal remains challenging in routine practice due to variable patient response, disease heterogeneity, and access to biologics. Diligent monitoring and individualized treatment escalation remain essential. Limitations include nominal p values in subgroup analyses and the need for further real-world validation. Overall, these insights invigorate the argument for early aggressive therapy in appropriate patients to forestall disease progression.
Conclusion
The phase 3 UNIFI study establishes that early disease clearance after ustekinumab induction is associated with significantly higher rates of long-term remission and improved quality of life in patients with moderate to severe ulcerative colitis. These findings reinforce the clinical imperative to promptly and comprehensively control mucosal inflammation in UC. Incorporating disease clearance as a therapeutic target could optimize treatment strategies and improve patient outcomes. Future research is warranted to extend these observations in broader populations and to explore complementary biomarkers for individualized care.
References
Danese S, Leong RW, Sands BE, Ma T, Marano C, Peyrin-Biroulet L. Clinical Trial: Association Between Early Disease Clearance and Long-Term Outcomes—4-Year Results From the Phase 3 UNIFI Study of Ustekinumab in Ulcerative Colitis. Aliment Pharmacol Ther. 2025 Sep;62(5):483-492. doi:10.1111/apt.70264. Epub 2025 Jul 16. PMID: 40668079; PMCID: PMC12343057.
